Aeterna Zentaris Announces Preclinical Data for AEZS-108 in Bladder Cancer Published Online in Oncotarget
Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced that preclinical data for the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LH-RH) analog, AEZS-108 (formerly AN-152), in urinary bladder cancer, have been published in the online edition of Oncotarget. The article outlines AEZS-108's powerful growth inhibition of bladder cancers in nude mice, as well as its safety profile.
Juergen Engel, PhD, President and CEO of Aeterna Zentaris stated, "Results of this study were the basis which warranted the development of AEZS-108 into the clinical stage and eventually led to the current Phase 2 trial in refractory bladder cancer conducted by lead investigator, Gustavo Fernandez, MD, of the University of Miami, Miller School of Medicine."
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.